{"transactions":[{"id":675222,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-26T22:11:29.000Z","date":"2026-08-24","kind":"grant","planned":false,"acquired":true,"shares":5800051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":5800051,"derivative":{"exercise_price":0.175,"expiration_date":"2036-08-23","underlying":"Common Stock","underlying_shares":5800051},"source":{"system":"sec-edgar","filing":"0002003059-26-000008","document":"wk-form4_1787782286.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000008/wk-form4_1787782286.xml","form_type":"4"}},{"id":832495,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:19:57.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":572000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":572000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":572000},"source":{"system":"sec-edgar","filing":"0002003059-26-000006","document":"wk-form4_1774037994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000006/wk-form4_1774037994.xml","form_type":"4"}},{"id":832494,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:19:57.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":562500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":562500,"derivative":{"exercise_price":0.45,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0002003059-26-000006","document":"wk-form4_1774037994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000006/wk-form4_1774037994.xml","form_type":"4"}},{"id":832493,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:19:57.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":572000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.13,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":572000},"source":{"system":"sec-edgar","filing":"0002003059-26-000006","document":"wk-form4_1774037994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000006/wk-form4_1774037994.xml","form_type":"4"}},{"id":832492,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:19:57.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":562500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.88,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0002003059-26-000006","document":"wk-form4_1774037994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000006/wk-form4_1774037994.xml","form_type":"4"}},{"id":952155,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:38:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":562500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":562500,"derivative":{"exercise_price":2.88,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0002003059-26-000003","document":"wk-form4_1767649136.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000003/wk-form4_1767649136.xml","form_type":"4"}},{"id":952154,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:38:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date."}],"balance_after":260898,"source":{"system":"sec-edgar","filing":"0002003059-26-000003","document":"wk-form4_1767649136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305926000003/wk-form4_1767649136.xml","form_type":"4"}},{"id":1027620,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:13:44.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":162500,"source":{"system":"sec-edgar","filing":"0002003059-25-000004","document":"wk-form4_1759436021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000200305925000004/wk-form4_1759436021.xml","form_type":"4"}},{"id":1219992,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T21:06:46.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":572000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":572000,"derivative":{"exercise_price":1.13,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":572000},"source":{"system":"sec-edgar","filing":"0001728117-25-000013","document":"wk-form4_1741295198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000172811725000013/wk-form4_1741295198.xml","form_type":"4"}},{"id":1473503,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-06-21T00:20:20.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.602,"value":15050.0,"ownership":{"direct":false,"nature":"By family trust"},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001728117-24-000072","document":"wk-form4_1718929213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000172811724000072/wk-form4_1718929213.xml","form_type":"4"}},{"id":1722235,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19562,"kind":"person","name":"Smith Robert Paul JR","position":1,"cik":"0002003059","reported_name":"Smith Robert Paul JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-05T22:12:24.000Z","date":"2023-12-04","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on December 4, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":1500000,"derivative":{"exercise_price":0.969,"expiration_date":"2033-12-03","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001728117-23-000164","document":"wk-form4_1701814328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003059/000172811723000164/wk-form4_1701814328.xml","form_type":"4"}}]}